# US 2010/0166797 A1 · Gammaretrovirus associated with cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166797 A1
- Document ID: US20100166797A1
- Status: Published application
- Kind: A1
- Application number: 11/903,756
- Filed: 2007-09-24
- Published: 2010-07-01
- Earliest claimed: 2005-12-19
- Assignees: The Cleveland Clinic Foundation; The Regents of the University of California
- Inventors: Robert H. Silverman; Eric A. Klein; Graham Casey; Joseph DeRisi; Don Ganem
- Web page: https://patentgrep.com/patent/US20100166797A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 16/112: Retroviridae (F), e.g. leukemia viruses
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12Q 1/701: {Specific hybridization probes}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/13021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12Q 2600/136: Screening for pharmacological compounds
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

## Claims

### Claim 1

An isolated XMRV present in a prostate tumor of an individual.

### Claim 2 (depends on 1)

The virus of claim 1 wherein the individual comprises a mutation in the hereditary prostate cancer-1 (HPC1) allele encoding an RNase L gene.

### Claim 3 (depends on 2)

The virus of claim 2 wherein the mutation is a homozygous mutation.

### Claim 4 (depends on 3)

The virus of claim 3 wherein the mutation is homozygous for the RNase L mutation R462Q.

### Claim 5

An isolated virus comprising a nucleic acid sequence having at least 94% identity to SEQ ID No: 1 or a complement thereof.

### Claim 6 (depends on 5)

The isolated virus of claim 5 wherein the nucleic acid sequence comprises SEQ ID No: 1 and a complement thereof.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

An isolated virus comprising SEQ ID No: 2.

### Claim 10

An isolated polypeptide comprising an amino acid sequence having at least 97% similarity to SEQ ID No: 3, 97% similarity to SEQ ID No: 4 or 94% similarity to SEQ ID No: 5.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The isolated polypeptide of claim 10 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and combinations thereof.

### Claim 14 (depends on 5)

A vector comprising the nucleic acid sequence of claim 5.

### Claim 15 (depends on 14)

A cell comprising the vector of claim 14.

### Claim 16 (depends on 1)

An antibody or antigen binding fragment thereof that specifically binds to the virus of claim 1.

### Claim 17 (depends on 16)

The antibody or antigen binding fragment of claim 16 wherein the antibody or antigen binding fragment binds to a gag polypeptide encoded by the virus.

### Claim 18 (depends on 17)

The antibody or antigen binding fragment of claim 17 wherein the gag polypeptide comprises SEQ ID No: 3.

### Claim 19

A method of detecting XMRV in a sample comprising:
a) contacting the sample with a nucleic acid sequence that hybridizes to all of a portion of an XMRV nucleic acid sequence under conditions in which a hybridization complex can occur between the nucleic acid sequence and the XMRV nucleic acid sequence; and
b) determining whether the hybridization complex is detected in the sample,
wherein if the hybridization complex is detected, then XMRV is in the sample.

### Claim 20

A method of detecting XMRV in a sample comprising:
a) contacting the sample with an antibody or antigen binding fragment thereof that specifically binds to an XMRV polypeptide under conditions in which a complex can occur between the antibody and the XMRV polypeptide; and
b) determining whether the complex is detected in the sample,
wherein if the complex is detected, then XMRV is in the sample.

### Claim 21

A method of identifying an agent that inhibits an XMRV comprising:
a) contacting the XMRV with an agent to be assessed; and
b) determining whether XMRV is inhibited in the presence of the agent,
wherein, if XMRV is inhibited in the presence of the agent, then the agent inhibits XMRV.

### Claim 22 (depends on 21)

The method of claim 21 wherein the activity of the XMRV in the presence of the agent is determined by measuring the ability of the XMRV to produce retroviral particles with reverse transcriptase activity.

### Claim 23

A method of inducing an immune response to an XMRV in an individual in need thereof, comprising administering to the individual an effective amount of an agent which induces an immune response to the XMRV in the individual upon administration.

### Claim 24 (depends on 23)

The method of claim 23 wherein the agent is selected from the group consisting of: a subunit of XMRV and an attenuated XMRV.

### Claim 25

A method of treating prostate cancer in an individual wherein XMRV is present in the prostate of the individual, comprising administering to the individual an effective amount of an agent that inhibits XMRV.

### Claim 26

A method of detecting asymptomatic (early stage) prostate cancer in an individual wherein XMRV is present in the prostate of the individual, comprising detecting the presence of an XMRV in the individual, wherein the presence of XMRV in the individual is indicative of early stage prostate cancer in the individual.

### Claim 27

A method of identifying an individual at risk for developing prostate cancer, comprising determining whether an XMRV is present in the individual, wherein if XMRV is present in the individual then the individual is at risk for developing prostate cancer.

### Claim 28 (depends on 27)

The method of claim 27 wherein the individual has a mutation in the hereditary prostate cancer-1 (HCP1) allele encoding an RNase L gene.

### Claim 29 (depends on 28)

The method of claim 28 wherein the mutation is a homozygous mutation.

### Claim 30 (depends on 29)

The method of claim 29 wherein the mutation is homozygous for the RNase L mutation R462Q.

### Claim 31

A kit for detecting the presence of XMRV in a sample comprising a labeled moiety that detects XMRV in a sample.

### Claim 32 (depends on 31)

The kit of claim 31 wherein the labeled moiety is a nucleic acid sequence that hybridizes to all of a portion of an XMRV nucleic acid sequence.

### Claim 33 (depends on 31)

The kit of claim 31 wherein the labeled moiety is an antibody or antigen binding fragment thereof that specifically binds to XMRV.

### Claim 34 (depends on 14)

A method of producing XMRV comprising maintaining the cell of claim 14 under conditions in which XMRV is produced.

### Claim 35 (depends on 33)

The method of claim 33 comprising isolating the XMRV produced by the cell.
